{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:34:33Z","timestamp":1793421273113,"version":"4.5.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Graves\u2019 orbitopathy (GO) is an autoimmune disease affecting the orbit and the retro-ocular tissues. GO pathogenesis involves multiple complex mechanisms, including the contribution of many inflammatory cytokines, such as interleukin-6 (IL-6). GO severity ranges from mild to severe and sight-threatening cases, with the latter affecting only a small percentage of patients. A considerable number of these patients do not respond to first-line immunosuppressive therapy with weekly intravenous pulses of corticosteroids and therefore, there is an unmet need for a second-line treatment, based on immunosuppressive drugs. In recent years tocilizumab (TCZ), an IL-6 inhibitor, has emerged as an effective and safe alternative option for the treatment of active, moderate-to-severe, refractory to steroids cases of GO. This review focuses on the up-to-date concepts regarding TCZ administration for the management of these patients.<\/jats:p>","DOI":"10.3389\/fendo.2025.1632531","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T04:12:33Z","timestamp":1757563953000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Current concepts of tocilizumab efficacy in active moderate-to-severe corticosteroid-resistant cases of Graves\u2019 orbitopathy"],"prefix":"10.3389","volume":"16","author":[{"given":"Georgios","family":"Boutzios","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Nikolopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Chatzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios G.","family":"Tzioufas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas V.","family":"Goules","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0905750","article-title":"Graves\u2019 ophthalmopathy","volume":"362","author":"Bahn","year":"2010","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/art.22033","article-title":"Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate","volume":"54","author":"Maini","year":"2006","journal-title":"Arthritis Rheumatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1210\/er.2002-0020","article-title":"Current perspective on the pathogenesis of Graves\u2019 disease and ophthalmopathy","volume":"24","author":"Prabhakar","year":"2003","journal-title":"Endocr Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.81.8.8768861","article-title":"Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves\u2019 disease","volume":"81","author":"Salvi","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1089\/105072501753210984","article-title":"Interleukin-6 stimulates thyrotropin receptor expression in human orbital preadipocyte fibroblasts from patients with Graves\u2019 ophthalmopathy","volume":"11","author":"Jyonouchi","year":"2001","journal-title":"Thyroid"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)91475-2","article-title":"Expression of thyrotropin-receptor mRNA in healthy and Graves\u2019 disease retro-orbital tissue","volume":"342","author":"Feliciello","year":"1993","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.82.6.2003","article-title":"Thyrotropin receptor transcripts in human adipose tissue","volume":"82","author":"Crisp","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/joim.13524","article-title":"Current concepts regarding Graves\u2019 orbitopathy","volume":"292","author":"Bartalena","year":"2022","journal-title":"J Intern Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1177\/25158414211027760","article-title":"Updates on the understanding and management of thyroid eye disease","volume":"13","author":"Men","year":"2021","journal-title":"Ther Adv Ophthalmol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a016295","article-title":"IL-6 in inflammation, immunity, and disease","volume":"6","author":"Tanaka","year":"2014","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3109\/08916939708996275","article-title":"High circulating IL-6 level in Graves\u2019 ophthalmopathy","volume":"25","author":"Moln\u00e1r","year":"1997","journal-title":"Autoimmunity"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2004.050807","article-title":"Quantification of cells expressing the thyrotropin receptor in extraocular muscles in thyroid associated orbitopathy","volume":"89","author":"Boschi","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-019-01116-4","article-title":"Immunohistochemical analysis of human orbital tissue in Graves\u2019 orbitopathy","volume":"43","author":"Hai","year":"2020","journal-title":"J Endocrinol Invest"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.648732","article-title":"Mechanisms that underly T cell immunity in graves\u2019 Orbitopathy","volume":"12","author":"Fang","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac328","article-title":"Understanding pathogenesis intersects with effective treatment for thyroid eye disease","volume":"107","author":"Smith","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.654473","article-title":"Cytokines as targets of novel therapies for graves\u2019 Ophthalmopathy","volume":"12","author":"Fallahi","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e19250","article-title":"Roles of four targets in the pathogenesis of graves\u2019 orbitopathy","volume":"9","author":"Ren","year":"2023","journal-title":"Heliyon"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13010072","article-title":"Immunological processes in the orbit and indications for current and potential drug targets","volume":"13","author":"Ciepli\u0144ska","year":"2023","journal-title":"J Clin Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2018.07.038","article-title":"Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant graves orbitopathy: A randomized clinical trial","volume":"195","author":"Perez-Moreiras","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9092816","article-title":"Anti-IL-6 receptor tocilizumab in refractory graves\u2019 Orbitopathy: national multicenter observational study of 48 patients","volume":"9","author":"S\u00e1nchez-Bilbao","year":"2020","journal-title":"J Clin Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10040706","article-title":"Steroid-resistant graves\u2019 Orbitopathy treated with tocilizumab in real-world clinical practice: A 9-year single-center experience","volume":"10","author":"P\u00e9rez-Moreiras","year":"2021","journal-title":"J Clin Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2023.0167","article-title":"Medical therapy in patients with moderate to severe, steroid-resistant, thyroid eye disease","volume":"33","author":"Toro-Tobon","year":"2023","journal-title":"Thyroid"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1186105","article-title":"Tocilizumab improves clinical outcome in patients with active corticosteroid-resistant moderate-to-severe Graves\u2019 orbitopathy: an observational study","volume":"14","author":"Boutzios","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B25","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10792-024-03117-6","article-title":"Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant thyroid eye disease: a prospective study","volume":"44","author":"Lee","year":"2024","journal-title":"Int Ophthalmol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2022.05.007","article-title":"Outcome of tocilizumab treatment in corticosteroid-resistant thyroid eye disease","volume":"160","author":"Pamp\u00edn-S\u00e1nchez","year":"2023","journal-title":"Med Clin (Barc)"},{"key":"B27","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ando.2020.01.003","article-title":"Tocilizumab in glucocorticoid-resistant graves orbitopathy. A case series report of a mexican population","volume":"81","author":"Ceballos-Mac\u00edas","year":"2020","journal-title":"Ann Endocrinol (Paris)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvae193","article-title":"Efficacy of tocilizumab in refractory graves orbitopathy from real-world clinical practice: an observational study","volume":"8","author":"Wang","year":"2024","journal-title":"J Endocr Soc"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000001346","article-title":"Subcutaneous tocilizumab for thyroid eye disease: simplified dosing and delivery","volume":"35","author":"Copperman","year":"2019","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"B30","doi-asserted-by":"publisher","first-page":"39","DOI":"10.4103\/tjo.tjo_59_21","article-title":"Subcutaneous tocilizumab for active thyroid eye disease refractory to orbital radiation and systemic steroids in tobacco smokers","volume":"12","author":"Stevens","year":"2022","journal-title":"Taiwan J Ophthalmol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000002027","article-title":"Tocilizumab for the management of thyroid-associated orbitopathy","volume":"38","author":"Smith","year":"2022","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"B32","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jcjo.2020.07.020","article-title":"Treatment of corticosteroid-resistant thyroid eye disease with subcutaneous tocilizumab","volume":"56","author":"Silkiss","year":"2021","journal-title":"Can J Ophthalmol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14655","article-title":"Long-term outcomes in corticosteroid-refractory Graves\u2019 orbitopathy treated with tocilizumab","volume":"97","author":"Moi","year":"2022","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2020.1808688","article-title":"Tocilizumab versus rituximab in patients with moderate to severe steroid-resistant graves\u2019 Orbitopathy","volume":"30","author":"Bennedja\u00ef","year":"2022","journal-title":"Ocul Immunol Inflamm"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0b013e3181e9a063","article-title":"Correlation between extraocular muscle size and motility restriction in thyroid eye disease","volume":"27","author":"Dagi","year":"2011","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-022-05727-1","article-title":"Extraocular muscle enlargement","volume":"260","author":"Rana","year":"2022","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-4294","article-title":"Risk factors for graves\u2019 Orbitopathy; the Australian thyroid-associated orbitopathy research (ATOR) study","volume":"101","author":"Khong","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12222","article-title":"Smoking and thyroid","volume":"79","author":"Wiersinga","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.615993","article-title":"Epidemiology, natural history, risk factors, and prevention of graves\u2019 Orbitopathy","volume":"11","author":"Bartalena","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000002525","article-title":"Statins in graves orbitopathy: A new therapeutic tool","volume":"39","author":"Lanzolla","year":"2023","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-018-0915-z","article-title":"Relationship between serum cholesterol and Graves\u2019 orbitopathy (GO): a confirmatory study","volume":"41","author":"Lanzolla","year":"2018","journal-title":"J Endocrinol Invest"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2017.0430","article-title":"High serum cholesterol is a novel risk factor for graves\u2019 Orbitopathy: results of a cross-sectional study","volume":"28","author":"Sabini","year":"2018","journal-title":"Thyroid"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2014.5103","article-title":"Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease","volume":"133","author":"Stein","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00238-2","article-title":"Statins for Graves\u2019 orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial","volume":"9","author":"Lanzolla","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab070","article-title":"Statins decrease the risk of orbitopathy in newly diagnosed patients with graves disease","volume":"106","author":"Nilsson","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.952954","article-title":"Research progress on the pathogenesis of Graves\u2019 ophthalmopathy: Based on immunity, noncoding RNA and exosomes","volume":"13","author":"Zheng","year":"2022","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-014-0487-4","article-title":"Circulating microRNA predicts insensitivity to glucocorticoid therapy in Graves\u2019 ophthalmopathy","volume":"49","author":"Shen","year":"2015","journal-title":"Endocrine"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1530\/ETJ-23-0083","article-title":"Circulating miR-146a predicts glucocorticoid response in thyroid eye disease","volume":"12","author":"Manso","year":"2023","journal-title":"Eur Thyroid J"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1632531\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T04:12:34Z","timestamp":1757563954000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1632531\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,11]]},"references-count":48,"alternative-id":["10.3389\/fendo.2025.1632531"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1632531","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,11]]},"article-number":"1632531"}}